LY6E

Across TCGA pan-cancer cohorts, LY6E RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated LY6E data layer compared with 2 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher LY6E RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LY6E expression acts as an unfavorable survival marker, although some lineages such as THCA and LUAD show a favorable association.

UCS, PAAD, and KIRP are the cancer types where LY6E RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Tertile	III,IV	0.357	0.815	<.001	66	view →
PAAD	DFS	Median	All	0.215	0.523	<.001	60	view →
KIRP	DFS	Tertile	III,IV	0.442	0.899	.001	58	view →
UVM	DFS	Median	III,IV	0.198	0.749	.003	58	view →
UCEC	OS	Tertile	All	0.544	0.830	.007	58	view →
THYM	OS	Median	All	0.686	1.000	.007	27	view →
LAML	DFS	Quartile	All	0.269	0.633	.008	26	view →
THCA	DFS	Tertile	All	0.909	0.636	.013	23	view →
LUAD	DFS	Median	IV	0.753	0.321	.015	16	view →
STAD	OS	Median	IV	0.176	0.511	.005	15	view →
LIHC	OS	Tertile	II,III,IV	0.302	0.511	.004	14	view →
COAD	DFS	Quartile	II,III,IV	0.381	0.798	.013	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

LY6E–UCS (OS)

Open the UCS breakdown →